Targeting residual cardiovascular risk in the statin era: cholesterol or inflammation?

医学 剩余风险 炎症 他汀类 胆固醇 羟甲基戊二酰辅酶A还原酶抑制剂 心脏病学 内科学 心血管事件 重症监护医学 疾病
作者
Giovanna Liuzzo,Carlo Patrono
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:44 (22): 1973-1975 被引量:9
标识
DOI:10.1093/eurheartj/ehad241
摘要

Comment on ‘Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials’, which was published in The Lancet, https://doi.org/10.1016/S0140-6736(23)00215-5. This collaborative analysis of patients with—or at high risk of—atherosclerotic cardiovascular disease (ASCVD), who were receiving contemporary statin treatment and were participants in three large randomized trials, evaluated the importance of high-sensitivity C-reactive protein (hs-CRP, a biomarker of residual inflammatory risk) and LDL-cholesterol (LDL-C, a biomarker of residual cholesterol risk) levels as predictors of future major adverse cardiovascular events (MACEs), cardiovascular death, and all-cause death.1 Hazard ratios (HRs) for cardiovascular events and deaths were calculated across quartiles of hs-CRP and LDL-C in analyses adjusted for age, gender, body mass index (BMI), smoking status, blood pressure, previous history of cardiovascular disease, and randomized treatment group assignment. Among the 31 245 patients included in the analysis from the Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) (n = 9988), A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin (REDUCE-IT) (n = 8179), and Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH) (n = 13 078) trials (mean age from 63 to 64 years, percentage of women from 29% to 35%, mean follow-up from 3 to 5 years), the percentage on a high-intensity statin (atorvastatin ≥40 mg once daily or rosuvastatin ≥20 mg once daily) ranged from 31% to 72%, across the three trials. The median baseline hs-CRP concentrations ranged from 2.1 mg/L to 2.3 mg/L and the median baseline LDL-C concentrations from 75 to 78 mg/dL. The quartile cut-points for both baseline hs-CRP and LDL-C were concordant across the three trials. The results were similar in each of the three trials separately and in the meta-analysis. Residual inflammatory risk, as measured by baseline hs-CRP, was significantly associated with incident MACEs [15.0% vs. 12.6%, highest hs-CRP quartile vs. lowest hs-CRP quartile; pooled adjusted HR 1.31, 95% confidence interval (CI) 1.20–1.43; P < 0.0001], cardiovascular mortality (5.4% vs. 2.1%; HR 2.68, 95% CI 2.22–3.23; P < 0·0001), and all-cause mortality (9.8% vs. 4.4%; HR 2.42, 95% CI 2.12–2.77; P < 0.0001). By contrast, the relationship of residual cholesterol risk was neutral for MACEs (13% vs. 13.6%, highest LDL-C quartile vs. lowest LDL-C quartile; pooled adjusted HR 1.07, 95% CI 0.98–1.17; P = 0.11), and of low magnitude for cardiovascular death (3.8% vs. 3.5%; HR 1.27, 95% CI 1.07–1·50; P = 0.0086) and all-cause death (6.6% vs. 6.7%; HR 1.16, 95% CI 1.03–1.32; P = 0.025). In combined analyses of the three trials, risks of future events were significantly higher in participants with both residual inflammatory risk and cholesterol risk (hs-CRP ≥2 mg/L and LDL-C ≥ 70 mg/dL, respectively) than in participants with neither residual inflammatory risk nor residual cholesterol risk (hs-CRP <2 mg/L and LDL-C < 70 mg/dL; all P values <0.0001). Risks of events were significantly higher in participants with hs-CRP ≥2 mg/L than in those with hs-CRP <2 mg/L, irrespective of LDL-C strata (all P values ≤0.0001). These effects were particularly strong for cardiovascular death and all-cause death. Lipid lowering is the cornerstone of prevention of atherosclerosis and its complications.2 However, cardiovascular events continue to occur frequently, even among individuals who achieve guideline-recommended LDL-C levels in response to lifestyle interventions and pharmacological treatments. In addition to aggressive LDL-C reduction and blood pressure control, efforts to target residual cardiovascular risk have focused on addressing systemic inflammation, hypertriglyceridaemia, platelets, and coagulation pathways.3 Inflammation plays multiple roles in the progression and destabilization of atherosclerotic disease. Nowadays, virtually all atherosclerotic patients are treated with statins, which lower both LDL-C and hs-CRP levels. Nevertheless, three randomized trials have shown that targeted anti-inflammatory therapy with canakinumab (which inhibits the interleukin-1β inflammatory pathway) or low-dose colchicine can significantly reduce cardiovascular event rates among patients with recent myocardial infarction or chronic coronary disease receiving statins in the absence of any reduction in LDL-C.4–7 Multiple agents beyond canakinumab and colchicine are being considered or are under active investigation in atherosclerotic disease trials, including upstream direct NLRP3 antagonists and downstream interleukin-6 inhibitors.3 Targeting inflammation in patients with or at high risk for ASCVD may require more individualized approaches than were needed for other risk factors.8 Moreover, as trials consistently show that further reductions in cardiovascular risk can be achieved with add-on lipid-lowering therapies in addition to statins, such as ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and inclisiran, most clinical guidelines worldwide have appropriately endorsed the notion that lower LDL-C is better.9 In the current analyses among patients receiving intensive statin therapy, the strength of the associations of residual inflammatory risk with cardiovascular events and mortality appeared to be greater than that of residual cholesterol risk.1 Advantages of this collaborative analysis were the large sample size that conferred sufficient statistical power to investigate associations between biomarkers and cardiovascular outcomes and the use of data from three contemporary trials in which all participants received intensive guideline-directed medical therapy. Within each trial, there were consistent biomarker measurements, accurate validation of patient characteristics and outcomes, and minimal loss to follow-up, thus reducing information and selection bias. The authors explicitly chose three trials that focused on triglyceride lowering to avoid settings in which either LDL-C or hs-CRP was a primary selection criterion for cohort recruitment, a limitation that occurred in previous studies comparing the prevalence of residual cholesterol risk and residual inflammatory risk in the setting of ezetimibe or PCSK9 inhibition.3 However, caution should be exercised in interpreting these results. First of all, association does not necessarily imply causation. Moreover, high-intensity statin use and diabetes are known confounders for the associations between cholesterol, inflammation, and cardiovascular events; however, Cox’s multivariable models did not account for these factors. Effect modification according to primary vs. secondary prevention was also not investigated. A further important issue is related to comparing HRs between separate Cox models for LDL-C and hs-CRP instead of comparing both in the same prediction model. Finally, residual inflammatory risk may appear to be more important than residual cholesterol risk in this analysis because patients were already receiving intensive statin therapy in the included trials. Surprisingly, a relatively modest increase in the risk of MACEs by moving from the lowest to the highest quartile of hs-CRP was associated with a substantial increase in mortality, whereas reducing hs-CRP with existing anti-inflammatory agents appears to produce appreciable reductions in MACEs without changing mortality.4–7 On the other hand, moving from the lowest to the highest quartile of LDL-C had no detectable effect on MACEs, whereas we know from phase 3 studies of PCSK9-inhibitors that further reducing LDL-C by ∼50%–60% does have a measurable impact on MACEs.10,11 Nevertheless, these findings are of potential clinical relevance. First, in secondary prevention, clinicians can measure hs-CRP along with LDL-C levels if they wish to understand the residual risks faced by their patients. Second, these data should not be interpreted as diminishing the critical role of lipid-lowering agents other than statins for patients with persistent or refractory hypercholesterolaemia but suggest that targeting LDL-C alone may not completely mitigate atherosclerotic risk, while anti-inflammatory treatment might provide incremental CV benefits. However, at present, most cardiologists are probably not yet ready to treat patients with ASCVD with a combination of lipid-lowering agents and anti-inflammatory drugs (essentially, low-dose colchicine), as the long-term risk-benefit profile of anti-inflammatory drug therapy has not been properly defined. The relatively short duration of both COLCOT5 and LoDoCo26 (23 and 29 months, respectively) is largely inadequate to assess the long-term safety of colchicine for secondary prevention of ASCVD.12 We clearly need to find more specific targets for cardiovascular inflammation to be tested in long-term clinical trials designed to enrol patients undergoing accurate immune phenotyping.8 No new data were generated or analysed in support of this research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
秋风的应助被南风采纳,获得30
刚刚
烟花的应助被小易采纳,获得10
刚刚
刚刚
慕青的应助被oreo采纳,获得10
1秒前
1秒前
1秒前
豆浆完成签到 ,获得积分10
1秒前
2秒前
水煮电吹风的应助被yjw0526采纳,获得10
2秒前
SciGPT的应助被siyue采纳,获得10
2秒前
gfhdf发布了新的文献求助10
3秒前
失眠的依白完成签到,获得积分20
3秒前
3秒前
4秒前
4秒前
5秒前
5秒前
5秒前
听书予你发布了新的文献求助10
5秒前
5秒前
张张完成签到,获得积分10
5秒前
研团子完成签到,获得积分10
5秒前
6秒前
阳光天磊发布了新的文献求助10
6秒前
6秒前
yangshuo发布了新的文献求助10
7秒前
7秒前
joey106完成签到,获得积分10
7秒前
7秒前
蟹xie发布了新的文献求助10
8秒前
lily关注了科研通微信公众号
8秒前
8秒前
gfhdf发布了新的文献求助10
8秒前
Camellia发布了新的文献求助10
8秒前
9秒前
qqq发布了新的文献求助30
9秒前
可爱的函函的应助被Ausna采纳,获得10
9秒前
gfhdf发布了新的文献求助10
9秒前
gfhdf发布了新的文献求助10
9秒前
gfhdf发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178102
求助须知:如何正确求助?哪些是违规求助? 9568769
关于积分的说明 21801545
捐赠科研通 7772898
什么是DOI,文献DOI怎么找? 3432613
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478199